![]() Triclabendazole (TCBZ, 6-chloro-5(2-3 dichlorophe-noxy)-2-methyl thio-benzimidazole), an halogenated benzimidazole (BZD) thiol derivative, shows high efficacy against both the immature and mature stages of Fasciola hepatica in sheep and cattle, which is a differential feature compared to other available trematodicidal drugs. Thus, the combined drug treatment did not reverse the poor efficacy of TCBZ against TCBZ-resistant F. No statistical differences (P > 0.05) were observed in fluke counts between treated groups and untreated control, which confirm the resistant status of the Sligo isolate.Ĭonclusions: The presence of IVM and MTZ did not affect the disposition kinetics of TCBZ and its metabolites. Efficacy values of 56 and 38% were observed for TCBZ alone and for the combined treatment, respectively. The AUC value of TCBZ.SO obtained after TCBZ administration (653.9 ± 140.6 |g.h/ml) was similar to that obtained after TCBZ co-administered with IVM and MTZ (650.7 ± 122.8 |g.h/ml). Results: The presence of IVM and MTZ did not affect the plasma disposition kinetics of TCBZ metabolites after the i.r. In the clinical efficacy study, the animals were sacrificed at 15 days post-treatment to evaluate the comparative efficacy against TCBZ-resistant F. Plasma samples were collected and analysed by HPLC. at 10 mg/kg) and TCBZ+IVM+MTZ treated sheep (10 i.r., 0.2 s.c. hepatica (Sligo isolate) were divided into three groups (n = 4): untreated control, TCBZ-treated (i.r. The aim of this work was to evaluate the pharmacokinetics and clinical efficacy of TCBZ administered alone or coadministered with ivermectin (IVM, efflux modulator) and methimazole (MTZ, metabolic inhibitor) in TCBZ-resistant F. Laura Ceballos ', Laura Moreno ', Luis Alvarez ', Laura Shaw, Ian Fairweather, Carlos Lanusse 'īackground: The reduced drug accumulation based on enhanced drug efflux and metabolic capacity, identified in triclabendazole (TCBZ)-resistant Fasciola hepatica may contribute to the development of resistance to TCBZ. Unchanged triclabendazole kinetics after coadministration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |